Latest news and press releases about Abivax S.A. (ABVX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19.
Price
| Price | $105.04 |
| Market Cap | $7.7B |
| Exchange | NASDAQ |
| Country | FR |
Valuation Ratios
| Price / Book | 14.31 |
| EV / EBITDA | -30.84 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -165.19% |
| Return on Invested Capital | -45.51% |
| Return on Assets | -57.52% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AXSM · CORT · CYTK · HALO · JAZZ · MDGL · MRUS
Explore sector: Healthcare · Biotechnology
More sections of ABVX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks